Get the Stockscreener App
2.71
0.39%
0.13
Lipella Pharmaceuticals Inc stock is traded at $2.71, with a volume of 15,310.
It is up +0.39% in the last 24 hours and up +3.60% over the past month.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
See More
Previous Close:
$2.58
Open:
$2.54
24h Volume:
15,310
Relative Volume:
0.01
Market Cap:
$6.12M
Revenue:
-
Net Income/Loss:
$-4.74M
P/E Ratio:
-3.6133
EPS:
-0.75
Net Cash Flow:
$-3.46M
1W Performance:
+7.92%
1M Performance:
+3.60%
6M Performance:
-21.20%
1Y Performance:
-54.30%
1-Day Range:
$2.54
$2.74
1-Week Range:
$2.03
$2.58
52-Week Range:
$1.965
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Name
Lipella Pharmaceuticals Inc
Sector
Industry
Phone
412-901-0315
Address
400 N LEXINGTON ST, PITTSBURGH
Compare LIPO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.6633 | 6.12M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.65 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
592.03 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
604.17 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
247.85 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.01 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
Analytical Overview: Lipella Pharmaceuticals Inc (LIPO)’s Ratios Tell a Financial Story - DWinneX
Lipella Pharmaceuticals Abstract on Oral Lichen Planus - GlobeNewswire
Clinical Data: New Treatment Breakthrough for Oral Lichen PlanusPhase 2a Trial Shows Remarkable Improvement - Stock Titan
LIPO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
LIPO stock’s current quarter earnings estimates: What analysts predict? - uspostnews.com
Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus - Reuters
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial - TipRanks
Lipella Reports Positive Phase 2a Results from Second - GlobeNewswire
Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success - Stock Titan
Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis - MarketBeat
Lipella Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Lipella Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lipella Pharmaceuticals expands preferred stock class - Investing.com Australia
Lipella Pharmaceuticals stock hits 52-week low at $2 By Investing.com - Investing.com Canada
Lipella Pharmaceuticals expands preferred stock class By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals stock hits 52-week low at $2 - Investing.com
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - The Manila Times
Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan
Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Tariffs and Tech Troubles Weigh on Markets - The Globe and Mail
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz
LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal
Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times
Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.
Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com India
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement - Yahoo Finance
Lipella Pharmaceuticals (LIPO) Expected to Announce Earnings on Tuesday - Defense World
FDA approves Lipella's oral treatment access program - MSN
Lipella Pharmaceuticals modifies agreement with Spartan Capital By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals modifies agreement with Spartan Capital - Investing.com
With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus - News & Insights
Analyzing Lipella Pharmaceuticals (NASDAQ:LIPO) and IDEAYA Biosciences (NASDAQ:IDYA) - Defense World
Lipella Pharmaceuticals Gains Buy Rating from Jason McCarthy Following Positive Phase 2a Results for LP-310 - TipRanks
3 Penny Stocks to Watch Now, 2/13/25 - TipRanks
Lipella Pharmaceuticals Announces Positive Phase 2a Results for LP-310 in Oral Lichen Planus Treatment - Defense World
Biotech Rips On Topline Analysis - The Globe and Mail
Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes - AOL.com
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Shares Rise After Positive Phase 2a Trial Results for Oral Lichen Planus Treatment - Marketscreener.com
Stock market news: Firefly Neuroscience +214.56%, Dominari Holdings +37.66% among top gainers during midday trading - Business Upturn
Stock market today: Firefly Neuroscience +60.32%, Dominari Holdings +36.36% among top gainers in early trading - Business Upturn
Lipella Pharmaceuticals Gains FDA Approval for LP-310 - TipRanks
Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):